Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JAGO RESEARCH AG HAS 10 DRUGS IN CLINICALS BASED ON GEOMATRIX

Executive Summary

JAGO RESEARCH AG HAS 10 DRUGS IN CLINICALS BASED ON GEOMATRIX timed- release technology. Jago, headquartered in Zollikon, Switzerland, indicated that some of the clinical trial results from the 10 drugs currently under study will be presented to FDA as part of U.S. drug approval registrations. While Jago holds the licensing rights to the Geomatrix system, the initial technology was developed by three Italian scientists at the University of Pavia, Italy. The only drug approved to date that uses the Geomatrix drug delivery system is Rhone-Poulenc Rorer's sustained-release diltiazem product Dilacor XR ("The Pink Sheet" June 15, T&G-5), which FDA approved on May 29. The Dilacor XR capsules contain a "degradable controlled- release tablet formulation" that is designed to release diltiazem over a 24-hour period. Jago said it derives some royalties from the sales. Other drug-delivery technologies in development by the Swiss firm are an aerosol inhalation therapy system that uses non- chlorofluorocarbon-containing propellants and a sustained-release gel delivery system for topical products. Jago was founded in 1983 by Jacques Conilla, PhD, the firm's president, chairman and CEO. The company has 50 employees at its Zollikon facility and a smaller division of 30 employees based in Como, Italy.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021106

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel